Safety and tolerability assessed by monitoring the frequency, duration, and severity of adverse events (AEs) according to National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.Evaluation of CD8 biomarkers from tumor and blood biospecimens. Here, CD8A is linked to neoplasm.